Daily Stock List
Pieris Pharmaceuticals, Inc. (PIRS)
Today we are highlighting Pieris Pharmaceuticals, Inc. (PIRS), here at the QualityStocks Daily Newsletter.
Founded in 2001, Pieris Pharmaceuticals, Inc. is a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies. A clinical-stage biotechnology enterprise, the Company is advancing the proprietary Anticalin® technology to create differentiated drugs, which have the potential to be safer and more effective than conventional approaches. Pieris Pharmaceuticals is based in Freising, Germany. The Company’s shares trade on the OTC Bulletin Board. Pieris Pharmaceuticals became a publicly traded company on December 18, 2014.
Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a broad array of molecules. The Company’s libraries of over 100 billion different Anticalins can virtually bind to any target of interest.
At present, Pieris Pharmaceuticals has a varied proprietary pipeline and has continuing research and development (R&D) collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. The Company’s objective is to become a fully integrated biotechnology company through developing Anticalin therapeutics in diseases with high unmet medical need and eventually commercializing its products.
Pieris Pharmaceuticals will engage with partners for many of its programs. However, the Company’s intention is to retain certain development and commercial rights to specific products as its experience in drug development continues to grow.
Its strategy includes advancing its lead drug candidates, PRS-080 (anti-hepcidin) and PRS-060 (anti-IL4Ra) into and through clinical trials. Its strategy is also to develop and broaden its Immuno-Oncology franchise, and to continue to build its platform through entering into new partnerships and advancing its currently-partnered programs.
This month, Pieris Pharmaceuticals announced the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for its PRS-080 program, a hepcidin antagonist to treat anemia. This study took place at a single site in Germany.
The study was a single dose escalating, blinded, placebo-controlled trial at a dose range from 0.08 to 16 mg/kg. The trial had 48 total subjects. Thirty-six were dosed with PRS-080 and twelve were dosed with placebo. In the study, no dose-limiting toxicities were observed and a maximum tolerated dose was not reached.
Pieris Pharmaceuticals’ plan is to present the coming unblinded data at a scientific conference in the second half of this year. In addition, Pieris announced that its intention is to start a first-in-patient trial by the end of this year in end-stage renal disease patients across multiple sites in Europe.
Pieris Pharmaceuticals, Inc. (PIRS), closed Tuesday's trading session at $4.20, up 5.00%, on 239,731 volume with 231 trades. The average volume for the last 60 days is 10,228 and the stock's 52-week low/high is $2.00/$4.25.
Wisdom Homes of America, Inc. (WOFA)
Today we are reporting on Wisdom Homes of America, Inc. (WOFA), here at the QualityStocks Daily Newsletter.
Founded in 2012, Wisdom Homes of America, Inc. is an owner and operator of manufactured homes retail centers. The Company has positioned itself to provide homebuyers the opportunity to purchase quality, affordable manufactured homes from its retail locations in Texas. Wisdom Homes of America has its corporate headquarters in Tyler, Texas. The Company’s shares trade on the OTC Markets Group’s OTCQB.
Wisdom Homes of America’s houses are systematically engineered and designed with state-of-the-art, computerized technology. This provides for premier quality, structure and affordability. The Manufactured Home is fully customizable and also eco-friendly and efficient. It permanently affixes to land and the set-up and installation is easy. A Manufactured Home provides for quality and a higher standard of construction. The Company has more than 1,000 models and variations.
Earlier this month, Wisdom Homes of America reported sales of $352,000 for May, 2015. Company Chief Executive Officer, Mr. Jim Pakulis, stated "May sales came in within our anticipated range for the month and we remain on target to generate $4 million in total sales for 2015. This will be a 400 percent increase over 2014 sales of approximately $1 million. In addition to being on track for May sales, we enjoyed strong sales during the first week of June.”
Last week, Wisdom Homes of America announced that it is continuing to execute on its development plan of opening 30 retail centers through adding another manufactured home retail center to its existing retail locations. Wisdom Homes has signed a three year lease for a retail center in Kerrville, Texas.
Mr. Brent Nelms, President of Wisdom Homes of America, stated, "As we have previously reported, our business model is predicated on opening retail centers, from which we can sell well built, affordable manufactured homes to prospective home buyers in the area, while concurrently, selling land/home packages in existing, established housing developments.”
Wisdom Homes of America, Inc. (WOFA), closed Tuesday's trading session at $0.0301, even for the day, on 75,001 volume with 6 trades. The average volume for the last 60 days is 42,700 and the stock's 52-week low/high is $0.0301/$0.17.
Generex Biotechnology Corp. (GNBT)
SmallCapVoice reported recently on Generex Biotechnology Corp. (GNBT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed Generex Biotechnology Corp. engages in the research, development, and commercialization of drug delivery systems and technologies. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity, with no deposit in the lungs. Its proprietary liquid formulations enable drugs normally administered through injection to undergo absorption into the body through the lining of the inner mouth using its proprietary RapidMist™ device. Its buccal insulin spray product is Generex Oral-lyn™.
Antigen Express, Inc. is a wholly-owned subsidiary of Generex Biotechnology. Antigen Express is a platform technology and product-based entity. The core platform technologies of Antigen Express consist of immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express is developing proprietary vaccine formulations for active immunotherapy and disease prevention.
The Antigen Express subsidiary has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One technology focuses on the modification of peptides with Ii-Key to increase potency. A second technology relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for strong stimulation of T-helper cells and prevents the further growth of cancer cells. Antigen Express is developing the AE37 breast cancer vaccine.
Generex Biotechnology’s RapidMist™ is an advanced buccal drug delivery technology. It consists of a proprietary formulation and a proprietary device design that can deliver drugs through the buccal mucosa safely. RapidMist™ has been shown to have a rapid onset of action with no lung deposition, precise dosage control, easy use and handling, and improved patient compliance.
The Company’s Generex Oral-lyn™ is an insulin spray for the treatment of Type I and Type II diabetes. Generex Oral-lyn™ is a safe, simple, fast, effective, as well as pain-free alternative to subcutaneous injections of prandial insulin. It is conveniently delivered to the membranes of the oral cavity by way of a straightforward asthma-like device with no pulmonary (lung) deposition.
Recently, Generex Biotechnology announced that it entered into a Memorandum of Understanding (MOU) with NHTherapeutics, Inc. The companies will co-develop a formulation for the delivery of Leuprolide into the human body through the buccal mucosa using the Generex proprietary RapidMist™ buccal drug delivery system. NHTherapeutics is a clinical stage pharmaceutical company. It focuses on GnRH agonism to treat conditions associated with decreased hormonal levels (hypogonadism) due to aging or disease and other endocrine disorders.
Generex Biotechnology Corp. (GNBT), closed Tuesday's trading session at $0.01518, up 1.20%, on 3,460,034 volume with 93 trades. The average volume for the last 60 days is 1,999,507 and the stock's 52-week low/high is $0.0105/$0.0388.
Net Medical Xpress Solutions, Inc. (NMXS)
Hawk Associates and SmallCapVoice reported this month on Net Medical Xpress Solutions, Inc. (NMXS), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Net Medical Xpress Solutions, Inc. is a leader in the telemedicine field. The OTCQB-listed Company provides telemedicine programs for diagnostic and clinical medical services. It provides these to mobile companies, urgent cares, and hospitals, trauma centers, imaging centers, jails, nursing homes, corporate health departments and outpatient medical facilities. Net Medical Xpress has four operating segments and greater than 500 physicians under contract. The Company is headquartered in Albuquerque, New Mexico.
Its Net Medical Xpress Specialists division provides telemedicine services to hospitals and other medical facilities. In addition, its Net Medical Xpress Staffing division established because of the purchase of MedTel Solutions, LLC. This division specializes in the recruitment and staffing of telemedicine physicians. Furthermore, this division offers home health care services - consultations with primary care.
The Company’s Net Medical Xpress Services division provides medical diagnostic reading services for radiology and cardiology. This division uses the same proprietary XR-EXpress software to provide these services to the customers of its Net Medical Xpress Solutions division. Its Net Medical Xpress Solutions division earns revenues from the development and marketing of proprietary internet technology-based software.
Net Medical Xpress has partnered with My OnCall Doc to use technology, operations, and other business associations. My OnCall Doc is an innovative on-demand provider of physician services. Its technology makes it easy to see and speak with doctors speedily and receive medical attention and in some cases non-schedule prescriptions.
Yesterday, Net Medical Xpress Solutions announced that it signed an agreement with telehealth consultant group T4 to provide telemedicine services for seven government hospitals in Iraq and Saudi Arabia.
Mr. Dick Govatski, Net Medical Chief Executive Officer, said, "HealthStar Networks is providing diagnostic equipment and coordinating the construction of modular hospitals for the program. Each hospital will have between 25 and 100 beds. The first two hospitals are expected to be deployed in the next 90 to 120 days. These will be state controlled hospitals targeted for the general population and supported by the government. Net Medical will provide primary care physicians as well as orthopedic surgeons, cardiologists, neurologists, and trauma specialists using our telemedicine technology."
Net Medical Xpress Solutions, Inc. (NMXS), closed Tuesday's trading session at $0.043, up 12.57%, on 130,972 volume with 16 trades. The average volume for the last 60 days is 43,562 and the stock's 52-week low/high is $0.012/$0.061.
HyperSolar, Inc. (HYSR)
Top Stock Picks, SmallCapStockPlays, TopPennyStockMovers, The MicrocapNews, and AimHighProfits reported earlier on HyperSolar, Inc. (HYSR), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
HyperSolar, Inc. is developing a pioneering, low cost technology to make renewable hydrogen using sunlight and any source of water. This includes seawater and wastewater. The Company’s solution is the HyperSolar H2Generator™. Its solar hydrogen generator eliminates the need for conventional electrolyzers. Hydrogen fuel usage produces pure water as the only by-product. HyperSolar is based in Santa Barbara, California and the Company lists on the OTCQB.
Through optimizing the science of water electrolysis at the nano-level, HyperSolar’s low cost nanoparticles mimic photosynthesis to efficiently use sunlight to separate hydrogen from water, to produce environmentally friendly renewable hydrogen. Its research focuses on developing a low-cost and submersible hydrogen production particle that can split water molecules under the sun, imitating the central functions of photosynthesis. Each particle is a complete hydrogen generator that contains a novel high voltage solar cell bonded to chemical catalysts by a proprietary encapsulation coating.
HyperSolar H2Generator™ Panels can be connected together to scale to any size system to meet application specific hydrogen requirements. The Company’s plan, utilizing its low cost method to produce renewable hydrogen, is to enable a world of distributed hydrogen production for renewable electricity and hydrogen fuel cell vehicles.
HyperSolar has reached a major technological milestone in its pursuit of clean hydrogen fuel production, through eliminating an expensive hydrogen-oxygen separation process. This will considerably reduce the overall system cost of hydrogen fuel production from sunlight.
HyperSolar has entered into a one year agreement with the University of Iowa (UOI). The agreement is to help expedite its research and development efforts to reach its objective of producing commercially viable renewable hydrogen. UOI has a reputation for innovative advancements in renewable energy technologies and sustainable practices in and around the campus.
HyperSolar has identified a low-cost aqueous process to produce artificial photosynthesis particles needed for water splitting. One of major challenges in solar-powered water splitting is the use of expensive, high voltage solar cells. HyperSolar’s research team at UOI successfully fabricated a hydrogen production particle with a low cost, high voltage solar cell to address this challenge.
This month, HyperSolar emphasized the importance of the Company’s recently identified low-cost, water-based manufacturing process. The innovative process positions HyperSolar to increase the voltage needed to produce renewable hydrogen using only sunlight.
Mr. Tim Young, HyperSolar Chief Executive Officer, said, "This breakthrough within the manufacturing process strengthens the Company's key objectives of driving down cost while improving efficiency."
HyperSolar, Inc. (HYSR), closed Tuesday's trading session at $0.02, down 3.38%, on 226,000 volume with 23 trades. The average volume for the last 60 days is 1,053,488 and the stock's 52-week low/high is $0.0111/$0.0449.
Galenfeha, Inc. (GLFH)
The QualityStocks Daily Newsletter would like to spotlight Galenfeha, Inc. (GLFH). Today, Galenfeha, Inc. closed trading at $0.35, up 12.90%, on 90,726 volume with 25 trades. The stock’s average daily volume over the past 60 days is 34,797, and its 52-week low/high is $0.1011/$4.00.
Galenfeha, Inc. was s pleased to announce today that the company will now be the OEM battery supplier for Louisiana-based Aviation Company SkyRunner, LLC. SkyRunner (www.flyskyrunner.com) tasked Galenfeha's Shreveport engineering and production facility with developing a proof of concept battery to start and power critical onboard systems for use in a new aviation unit. The Galenfeha team produced prototypes that tested flawlessly, leading to a supplier agreement signed on June 13, 2015.
Galenfeha, Inc. (GLFH) is an engineering, product development, and manufacturing company that provides innovative solutions for oil and natural gas production, as well as stored energy products across a number of different industries. The company provides these products and services through its stored energy and oil & gas division.
Through its stored energy division, Galenfeha offers one of the most powerful, environmentally friendly battery systems in the market. The batteries have onboard computers, are inherently safe, internally temperature regulated, have optional GPS monitoring capabilities, offer significant weight reduction of up to 50%, and are engineered specifically for each type of application. Features include 100% “green” chemistry, RoHS compliancy, and active short circuit protection control.
Through its oil and gas division, the company offers chemical injection pumps that merge the perceived benefits of a hybrid, electric over pneumatic system. Galenfeha management believes the combination of the two parameter control systems represents a measurable shift in efficiency, reliability, cost management, and profitability to individual well locations as well as entire production fields. The combined technologies have demonstrated increased chemical injection accuracy, reducing chemical contamination in the production process while controlling cost and waste.
The company’s unwavering dedication is to continuously develop products that perform better than conventional solutions while also reducing environmental impact. Leveraging the management team’s wealth of resources and relationships, Galenfeha is well positioned for continued growth as the company aims to expand in both the stored energy and oil & gas industries. Disclaimer
Galenfeha, Inc. Company Blog
Galenfeha, Inc. News:
Galenfeha Stored Energy Solutions Enters Aviation Industry
Galenfeha Broadens Oil and Gas Industry Penetration
Lithium Iron Phosphate Battery Tech: Providing Better Performance and Environmental Sustainability
Save The World Air, Inc. (ZERO)
The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.36, off by 2.47%, on 196,373 volume with 53 trades. The stock’s average daily volume over the past 60 days is 105,223, and its 52-week low/high is $0.3221/$0.839.
Save The World Air, Inc. held its annual meeting of stockholders on June 19, 2015, during which all resolutions put to the meeting were adopted. Greggory Bigger, STWA Chairman and Chief Executive Officer commented, "I am thrilled with the resounding success of our shareholder meeting. On behalf of our executive management team and Board of Directors, I'd like to express our sincere gratitude to our loyal shareholders for their continued support, the majority of whom voted to pass very meaningful and important initiatives for our Company. I also want to specifically point out our many international shareholders who have been so supportive, and let them know that we may look at the opportunity to bring the meeting to London or Sydney in the future. I look forward to continuing discussions, and to providing shareholders with updates on our progress as material events occur."
Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.
In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.
The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.
STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.
Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer
Save The World Air, Inc. Company Blog
Save The World Air, Inc. News:
STWA Holds 2015 Annual Stockholders Meeting
STWA Deploys Joule Heat Direct Heating System on Gathering Line for Crude Oil Pipeline in Uintah Basin
STWA Congratulates Pipeline Research Council International on New Technology Development Center
View Systems, Inc. (VSYM)
The QualityStocks Daily Newsletter would like to spotlight View Systems, Inc. (VSYM). Today, View Systems, Inc. closed trading at $0.0054, up 12.50%, on 603,090 volume with 5 trades. The stock’s average daily volume over the past 60 days is 607,156, and its 52-week low/high is $0.0042/$0.0325.
View Systems, Inc. (VSYM) is a leading security technology products company with “state-of-the-art” technological solutions for modern security problems. Targeting the challenging business opportunities in the opening decades of the 21st century and beyond, View Systems has solutions for law enforcement facilities such as correctional institutions as well as other government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.
The senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry. The approach used by View Systems utilizes the expertise of this team to provide innovative solutions to security problems with reliable “cutting edge” products in conjunction with client-oriented security consulting services.
The company’s flagship product, ViewScan, is an advanced walk-through Concealed Weapons Detection System (CWD) that greatly simplifies the process of discriminating suspicious items from harmless ones. The highly sensitive, completely passive sensor technology powering the system accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles. A portable version of this system has only a fifteen minute setup time using only a screwdriver and it easily fits inside a golf size case.
Experts say the security industry has been the fastest-growing sector of the global economy during the past decade. Today, it is conservatively estimated to be a $100 billion-a-year industry and growing. As the business environment continues to get more complex, especially in foreign markets, View Systems is strategically positioned to capitalize on unsurpassed opportunity. Disclaimer
View Systems, Inc. Company Blog
View Systems, Inc. News:
View Systems, Inc. Files for Patent, Begins Manufacturing of Enhanced ViewScan Product
View Systems Continues to Install Its Proprietary Scanning Systems Nationwide
View Systems, Inc. (VSYM) Announces Engagement of QualityStocks Investor Relations Services
One World Holdings, Inc. (OWOO)
The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0083, up 5.06%, on 56,057,198 volume with 697 trades. The stock’s average daily volume over the past 60 days is 6,532,702, and its 52-week low/high is $0.0008/$0.05.
One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.
In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.
The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.
Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer
One World Holdings, Inc. Company Blog
One World Holdings, Inc. News:
The One World Doll Project to Give Updates on National Wal-Mart Roll Out and Business Expansion Plans on Quarterly Conference
Fortune Article Highlights The One World Doll Project's Retail Success
Walmart Deal Secured; The One World Doll Project Founder Interviews With CEOLIVE.TV
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.048, up 4.35%, on 786,710 volume with 50 trades. The stock’s average daily volume over the past 60 days is 736,795, and its 52-week low/high is $0.045/$0.148.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation to Present at International Society for Cellular Therapy Annual Meeting
International Stem Cell Corporation Announces 2015 First Quarter Results
International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
Today's Top 3
INO.com Market Report
Fast Money Alerts
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Aristocrat Group Corp. (ASCC) to Enter New Market as a Standout
- Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services
- Cleartronic, Inc. (CLRI) Subsidiary Signs Agreement With Edmonton International Airport
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Enters Second Power Provider Agreement in the Democratic Republic of the Congo
- Galenfeha, Inc. (GLFH) Stored Energy Solutions Enters Aviation Industry
- Growblox Sciences, Inc. (GBLX) Receives Funding to Complete Construction of Nevada Cultivation Facility
- International Stem Cell Corp. (ISCO) to Present at International Society for Cellular Therapy Annual Meeting
- Loans4Less.com Inc. (LFLS) Enters into an Acquisition Agreement with 321LEND
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Begins Operating And Buys Control Of North American Shopping Network Simbadeals.com From DoMark International
- One World Holdings, Inc. (OWOO) The One World Doll Project to Give Updates on National Wal-Mart Roll Out and Business Expansion Plans on Quarterly Conference
- Pure Hospitality Solutions, Inc. (PNOW) Releases Oveedia Site Snapshots
- Save The World Air, Inc. (ZERO) Holds 2015 Annual Stockholders Meeting
- View Systems, Inc. (VSYM) Files for Patent, Begins Manufacturing of Enhanced ViewScan Product
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors
- WRIT Media Group, Inc. (WRIT) Featured in Exclusive QualityStocks Production Video